Tech Company Financing Transactions
SiteOne Therapeutics Funding Round
SiteOne Therapeutics, operating out of Bozeman, secured $100 million in funding from Novo Holdings, Mission BioCapital and OrbiMed.
Transaction Overview
Company Name
Announced On
12/18/2024
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds for the advancement of its portfolio of selective, small molecule ion channel modulators for the treatment of sensory hyperexcitability disorders through human clinical proof of concept.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
203 Enterprise Blvd. 3
Bozeman, MT 59718
USA
Bozeman, MT 59718
USA
Phone
Website
Email Address
Overview
SiteOne Therapeutics, located in San Francisco, is developing novel therapeutics and diagnostics to safely, effectively and efficiently treat acute and chronic pain without the limitations of existing therapies, such as NSAIDs and opioids.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stan Abel
Controller
Anne Martin
VP - Bus. Development
Debra Odink
VP - R & D
John Mulcahy
Browse more venture capital transactions:
Prev: 12/18/2024: Plume venture capital transaction
Next: 12/19/2024: Deep Sky venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. VC investment data records on this site are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs